✨ Health Notices
NEW ZEALAND GAZETTE, No. 51
14 APRIL 2011
Health
Intellectual Disability (Compulsory Care and Rehabilitation) Act 2003
Appointment of Compulsory Care Co-ordinators
Under section 140 of the Intellectual Disability (Compulsory Care and Rehabilitation) Act 2003, I appoint the following person as a compulsory care co-ordinator for the named geographical and operational areas listed below.
Northern region, being the geographical area including Auckland and Northland:
Gary Wyattland:
The appointment of the above-named person takes effect on the date this notice is published in the New Zealand Gazette and ends on 30 April 2014.
Dated at Wellington this 6th day of April 2011.
KEVIN WOODS, Director-General of Health.
go2361
Medicines Act 1981
Corrigendum—Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health gave his consent to the distribution in New Zealand of the new medicines listed in the Schedule to a notice published in the New Zealand Gazette, 28 October 2010, No. 46, page 3651.
This corrigendum amends the notice by replacing the entry for the product Sativex with the following entry:
Product: Sativex
Active Ingredients: Cannabidiol 25mg/mL equivalent to cannabis sativa extract 35mg–42mg
Tetrahydrocannabinol 27mg/mL equivalent to cannabis sativa extract 36mg–44mg
Dosage Form: Oral spray
New Zealand Sponsor: Health Support Limited
Manufacturer: CP Pharmaceuticals Limited, Wrexham, United Kingdom
Dated this 7th day of April 2011.
MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go2413
Provisional Consent to the Distribution of New Medicines
Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Loniten
Active Ingredient: Minoxidil 10mg
Dosage Form: Tablet
New Zealand Sponsor: Pfizer New Zealand Limited
Manufacturer: Patheon Inc, Ontario, Canada
Note: This consent is valid for two years from the date of publication of this notice.
Product: Metaraminol
Active Ingredient: Metaraminol tartrate 0.949g/L equivalent to metaraminol base 0.50g
Dosage Form: Solution for infusion
New Zealand Sponsor: Biomed Limited
Manufacturer: Biomed Limited, Auckland, New Zealand
Note: This consent is valid for two years from the date of publication of this notice.
Product: Metaraminol
Active Ingredient: Metaraminol tartrate 1.898g/L equivalent to metaraminol base 1.0g
Dosage Form: Solution for infusion
New Zealand Sponsor: Biomed Limited
Manufacturer: Biomed Limited, Auckland, New Zealand
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 7th day of April 2011.
MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go2411
Next Page →
NZ Gazette 2011, No 51
✨ LLM interpretation of page content
🏥 Appointment of Compulsory Care Co-ordinator
🏥 Health & Social Welfare6 April 2011
Intellectual Disability Act 2003, Compulsory Care Co-ordinator, Northern Region
- Gary Wyattland, Appointed Compulsory Care Co-ordinator
- KEVIN WOODS, Director-General of Health
🏥 Corrigendum to Consent for Distribution of New Medicine
🏥 Health & Social Welfare7 April 2011
Medicines Act 1981, Sativex, Cannabidiol, Tetrahydrocannabinol
- MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health
🏥 Provisional Consent to Distribution of New Medicines
🏥 Health & Social Welfare7 April 2011
Medicines Act 1981, Loniten, Metaraminol, Provisional Consent
- MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health